We recently published 10 Stocks Hammered Harder Than Wall Street. Viking Therapeutics, Inc. (NASDAQ:VKTX) is one of Tuesday’s ...

Viking (NYSE: VIK) stock is down approximately 3% after the cruise line’s second-quarter earnings report. The company ...

Viking Therapeutics' stock drops 40% despite strong Phase 2 weight-loss drug results. See here to know why I remain ultra bullish on VKTX stock.

In the second quarter, attributable net income increased by 45 percent to 1.5 billion yuan from 1.067 billion yuan in the ...

In April 2025 , Northstrive Biosciences announced it received preliminary feedback from the FDA on its planned Type B pre-IND ...

The latest health news covers underwhelming results from Viking's weight-loss pill, potential tax exemptions on health insurance in India, Brazil's declining chicken exports due to bird flu, U.S.

William Blair starts Kyverna coverage with Outperform, citing KYV-101's potential as the first FDA-approved CAR-T therapy in ...

Shares of Viking Therapeutics VKTX plunged 42% yesterday after it reported top-line data from the phase II VENTURE-Oral ...

In this week’s edition of InnovationRx, we look at Phil Knight’s big cancer gift, Medallion’s credentialing clearinghouse, a ...

After Viking Therapeutics (VKTX) yesterday announced 13-week Phase 2 data for VK2735, an oral GIP/GLP-1-based candidate for obesity, Mizuho notes ...

The oral formulation led to up to 12.2% weight loss over three months, a weaker outcome versus late-stage treatments from Eli ...

Current health news highlights include Viking's weight-loss pill failing to meet financial expectations, European corporate ...